Page 7 - Pharmascience Inc News Today

A trio of high blood pressure medications are being recalled due to the presence of an impurity.

  WINNIPEG -- Health Canada has issued a recall covering three types of blood pressure drugs from the class of medication known as sartans.’ A news release from Health Canada lists the three drugs recalled, which are produced by several manufacturers, as irbesartan, losartan and valsartan. Sartans are prescribed to treat patients with high blood pressure to help prevent heart attacks and stroke. They are also used in patients with heart failure or those who have had a recent heart attack...

Today the Lancet Respiratory Medicine published the results of the Montreal Heart Institute's (MHI) COLCORONA study on the prevention of morbidity and mortality related to COVID-19. Pharmascience Inc., one of the largest Canadian-owned pharmaceutical companies, has supported this study since its inception.

MONTREAL, May 28, 2021 (GLOBE NEWSWIRE) — The Montreal Heart Institute (MHI) announces that the COLCORONA study results are published in The Lancet…

Colchicine could be considered as a treatment for non-hospitalized patients diagnosed with COVID-19 by PCR test and at risk of complicationsMONTREAL, May 28, 2021 (GLOBE NEWSWIRE) -- The Montreal Heart

Search jobs 12-Apr-2021 [2021] Saline Laxatives Market is Expected to Surge with 5.0% CAGR With US$ 613.3 Million by 2027 – Coherent Market Insights SEATTLE, April 12, 2021, (PHARMIWEB) — The global saline laxatives market, by Age Group (Pediatric and Adult), By Route of Administration (Oral and Rectal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, As...

Canadian Patent No. 2,461,202 (the  202 Patent), which was asserted by Bristol-Myers Squibb Canada Co. and Bristol-Myers Squibb Holdings Ireland Unlimited Company (collectively,  BMS). The 202 Patent claims the active ingredient apixaban and its use for the treatment and prevention of thromboembolic disorders (blood clots). Canadian Patent No. 2,791,171 (the  171 Patent), which was asserted by BMS and Pfizer Inc. (collectively,  BMS & Pfizer). The 171 Patent claims tablet formulations of ap...

Canmar 5 was a trend for a day or here to stay. This year, the Federal Court has seen increased attempts by litigants to resolve matters more expeditiously by way of dispositive motions. Summary judgment was granted in three cases 6 and two motions for default judgment were brought but dismissed based on insufficient evidence. ViiV Healthcare Company v. Gilead Sciences Canada, 8 the Court held that completion of discoveries is not a precondition to summary trial such that resolution may be s...

Investegate announcements from Montreal Heart Institute, Colchicine reduces the risk of COVID-19-related complications

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Colchicine reduces the risk of COVID-19-related complications Montreal Heart InstituteJanuary 23, 2021 GMT MONTREAL, Jan. 22, 2021 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of dea...